Patients with EASI of 5 or less had significantly higher oSCORAD when moderate-severe versus no-mild lesions were localized to the face (29.3 6 9.5 vs 18.1 6 9.9; P <.0001), eyelids (30.5 6 11.2 vs 18.4 6 9.8; P < .0001), neck (31. 4 6 10.8 vs 18.7 6 10.0; P < .0001), hands (30.9 6 9.5 vs 18.5 6 10.0; P < .0001), and feet (34. 4 6 12.9 vs 19.1 6 10.3; P 5 .02 ).
The present study shows a complex relationship between EASI and oSCORAD/SCORAD and several limitations of both measures. Xerosis and/or oozing/weeping were associated with significantly higher oSCORAD, but low EASI. This is because xerosis and oozing/weeping are scored in oS-CORAD, but not in EASI. Patients with low EASI had higher oSCORAD secondary to localized moderate-severe lesions, and higher POEM scores. EASI assesses 4 AD signs and weights them to the BSA-affecting 4 sites. oSCORAD/ SCORAD assesses 6 AD signs separately from BSA, with representative lesional intensity comprising 76%/61% of the total score. Thus, patients with localized moderate-severe lesions may have high oSCORAD, but low EASI. Selection of a representative lesion in oSCORAD/SCORAD might bias toward reporting more severe disease. However, this does not appear to be the case because oSCORAD/SCORAD showed a closer relationship with POEM than with EASI. EASI and SCORAD were not perfectly correlated with POEM. Although each of these is a validated AD outcome measure, it may be that no single assessment is adequate for assessing the full severity and/or burden of AD. Of note, the 3 signs most closely associated with patient-reported AD severity (erythema, excoriation, and edema/papulation) 5 are present in EASI and oSCORAD/SCORAD.
Low EASI scores encompass a heterogeneous group of patients, including some having fairly extensive milder lesions and localized moderate-severe lesions. Studies of mild AD that use low EASI scores as an inclusion criterion may enroll a diverse mixture of patients with different extent and lesional severity. These results shed light on the interpretation of EASI scores in the mild range. Previous interpretability studies found that EASI scores of 0 to 7.0 encompass almost clear or mild AD, 6 yet this encompasses a heterogeneous group of patients. In EASI, the lowest surface area category is quite broad at 1% to 9% and equally weights cases with a 1-cm plaque or 9% of the body site affected. EASI may be a poorer measurer than oSCORAD when assessing patients with more limited disease. Alternatively, it is possible that oSCORAD/SCORAD is a poor measure of mild disease with too broad a range of values. We believe this to be less likely, because unlike EASI, the oS-CORAD/SCORAD scores had linear relationships with POEM. Nevertheless, inclusion of xerosis in the oSCORAD/ SCORAD might reduce its responsiveness, because xerosis may be present in the absence of active AD lesions. Moreover, assessing xerosis can be challenging in clinical trials because it varies by the frequency, vehicle, and time of last application of emollients/moisturizers.
In conclusion, the present results provide further support for the inclusion of oSCORAD and/or SCORAD in addition to EASI in clinical trials. oSCORAD/SCORAD correlated better with POEM than did EASI. However, the merits of assessing both EASI and SCORAD in trials has to be weighed against the excess burden of data collection for investigators and patients, as well as difficulties in training investigators in how to assess both scales. To the Editor: Chronic urticaria is a frequent skin disease characterized by the sudden appearance of wheals, angioedema, or both for >6 weeks.
1 It can be divided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria. 1 Many affected patients do not respond sufficiently to first-and second-line treatment 2, 3 and the disease activity may also change considerably over time. 4 Therefore, most patients and their physicians have to repeatedly decide whether the current treatment is sufficient or whether an adjustment is needed. Moreover, the costs of the guideline-recommended therapies 1 increase with each level, and 3 of the 5 treatment options are off-label (only H 1 -antihistamines in regular doses and omalizumab are currently licensed for CSU). Accordingly, a regular and standardized evaluation of disease control during the course of disease may help to guide treatment decisions, to back these decisions with a valid and reliable documentation, and to monitor treatment outcome. To enable this evaluation and documentation, we recently developed the Urticaria Control Test (UCT). 4 However, the UCT's responsiveness to changes in disease control, for example in response to treatment adjustment, as well as UCT score changes that can be considered clinically relevant, have not yet been sufficiently studied. To address these gaps, we investigated the responsiveness of the UCT and its minimal important difference (MID). We investigated 65 consecutive adult patients with difficult-totreat CSU (ie, patients with insufficient responses to regular and increased doses of second-generation H 1 -antihistamines). After an initial assessment of patient characteristics (see Tables E1  and E2 in this article's Online Repository at www.jacionline. org), all patients were asked to continue their current treatment (second-generation H 1 -antihistamines in < _4 times the licensed dose) for 2 more weeks and to prospectively document their disease activity with the Urticaria Activity Score (UAS). At the end of the 2 weeks (baseline), the patients completed the UCT, the Chronic Urticaria Quality of Life Questionnaire (CU-Q 2 oL), the Dermatology Life Quality Index (DLQI), and they answered additional questions addressing the efficacy of their treatment and their current level of disease control (for details on the outcome tools and the handling of missing values see the Methods section in this article's Online Repository at www. jacionline.org). Subsequently, all patients received their first injection of omalizumab 300 mg and were asked to document their symptoms for another 4 weeks with the UAS. At the end of the 4 weeks (follow-up), all patients were asked to complete the UCT, CUQ 2 oL, and DLQI as well as the additional questions for a second time. In addition, the treating physicians rated the response to treatment with omalizumab. After the first injection of omalizumab all patients continued their treatment with H 1 -antihistamines in < _4 times the licensed dose, but they were allowed to stop in case they reached complete symptom control.
Four weeks after the initiation of omalizumab treatment, disease control, disease activity, and health-related quality of life (HR-QoL) were improved as compared to baseline (see Table  E2 and Fig E1 in this article's Online Repository at www. jacionline.org). UCT score changes from baseline to follow-up correlated strongly with changes of the UAS7 (r 5 20.63) and CU-Q 2 oL total score (r 5 20.71), and showed a good correlation with changes in DLQI scores (r 5 20.49) (see Table I , and see Fig  E2 in this article's Online Repository at www.jacionline.org). Moreover, the UCT results also strongly correlated with changes in the patients' self-evaluation of their treatment efficacy and with the physicians' global assessment of the treatment response (see Tables E3 and E4 in this article's Online Repository at www. jacionline.org). When treatment responses were categorized by changes in the UAS7, the current gold standard of disease activity assessment in CSU, 77% of ''complete responders'' were found to change from a UCT score of <12 points (indicating poorly controlled disease) at baseline to > _12 points (indicating wellcontrolled disease) during omalizumab therapy. In contrast, this was only the case in 20% of ''partial responders'' and none of the ''nonresponders'' (Table II) .
MID is the smallest change in a score that can be considered clinically relevant. To determine the UCT's MID, anchor-based and distribution-criterion-based approaches were applied. During the anchor-based approaches, the patient's global assessment of their disease control (PatGA-disease control) was used as anchor. As expected, UCT scores were found to be increased with an improved PatGA-disease control at follow-up (see Fig E3 in this article's Online Repository at www.jacionline.org) and the correlation between changes in both outcome measures was strong (r 5 0.84, P < .001, n 5 61), confirming that PatGA-disease control is an adequate anchor. The mean UCT score increase 6 SD in case of the smallest possible improvement in the PatGA-disease control (improvements by 1 step on its Likert scale rating) was found to be 4.0 6 2.6 points. In contrast, in case of an unchanged PatGA-disease control rating, the mean UCT score changed only by 1.3 6 1.9 points. Accordingly, the mean change method 5, 6 suggests a MID of 4 points.
A receiver operating characteristic (ROC) curve analysis 7 was applied as the second anchor-based method (see Fig E4 in this article's Online Repository at www.jacionline.org). Here, the cutoff point for UCT score changes with the best balance of sensitivity, and specificity for a meaningful improvement of disease control was found to be 3 points. At this cutoff point, the sum of the percentage of misclassified patients was lowest (Table III) . Accordingly, the ROC curve analysis suggests a MID of 3 points. For the distributional-criterion approach, the SD of the baseline UCT scores (3.2) was divided by 2.
8 Accordingly, a MID of 1.6 (2 points) is suggested by this (indirect) calculation.
In addition to the MID, the smallest detectable change of the UCT score was calculated. For more information see the Results section in this article's Online Repository at www.jacionline.org.
The UCT is a simple, valid, and reliable patient-reported outcome (PRO) measure that was originally developed to determine disease control in CU patients and to guide treatment decisions. 4 Here we report, that the UCT is also suited to determine changes in disease control over time and to assess treatment effects (that it is responsive to change). Our results demonstrate that changes in the UCT score strongly correlate with disease-specific assessments of changes in urticaria activity (UAS7) and HR-QoL (CU-Q 2 oL), while the correlation with changes in the less-specific DLQI are less strong (but still good). Importantly, the change of UCT ratings from ''poorly controlled'' to ''well-controlled,'' was well in accordance with the change of the patients' self-assessment of treatment efficacy, with the physicians' global assessment of the treatment response, and with the UAS7-based assessment of treatment response. This supports the appropriateness of the current UCT cutoff value of > _12 points to detect patients with wellcontrolled urticaria.
The knowledge of the MID of an outcome measure is important for the interpretation of changes in its score.
9 By 0.592 P < .001 n 5 46 CU-Q 2 oL total score 0.749 P < .001 n 5 62 *Changes from baseline to 4 weeks after the first omalizumab injection (300 mg). The correlation coefficient is negative because in case of an improvement, the UCT score increases while the scores of the UAS7, CU-Q 2 oL, and the DLQI decrease. applying 2 anchor-based approaches, the ''mean change method'' and the ROC curve analysis, we found a MID for UCT score improvements of 4 and 3 points, respectively. The distribution-criterion-based analysis suggested a MID of 2 points. In line with other investigator, 10 we prefer the direct and patient anchor-based approach over the indirect distributional-criterion approach. Moreover, we prefer the results from the ROC curve analysis over the ''mean change method'' results, as the ROC curve analysis also includes subjects who did not improve in their disease control. Accordingly, we regard a MID of 3 points as most appropriate for UCT score changes. Supplemental discussion of this study including its limitations are provided in the Discussion section in this article's Online Repository at www.jacionline.org.
In conclusion, the UCT is a suitable tool for assessing levels and changes of disease control in patients with CU. MID of the UCT, in other words, the minimal score change that mirrors a clinically relevant change of disease control for the individual patient, was found to be 3 points.
We thank all patients who made this study possible and the members of the Urticaria Specialty Clinic Berlin for their help during this project, especially Nicole Klameth, Nadja Tampier, Max Spindler, and Hesna G€ ozl€ ukaya. We also thank Robert F. Ofenloch from Department of Clinical and Social Medicine, University Hospital Heidelberg, Germany, for helpful discussions related to the SDC data. Finally, we thank the Urticaria Network eV (www. urtikaria.net) and the Urtikaria Netzwerk Berlin Brandenburg eV (www. urtikaria-netzwerk-bb.de) for supporting this work. *For this analysis of cutoff values, change of urticaria control was categorized into ''improved'' (patients' global assessment of disease control was improved by > _ 1 category from baseline to 4 weeks after initiation of omalizumab treatment) or ''not improved'' (patients' global assessment of disease control was unchanged or even worse 4 weeks after initiation of omalizumab). Sum of % misclassified 5 (1 2 sensitivity) 1 (1 2 specificity).
TABLE II. Changes* in the UCT score related to the patients treatment response based on the UAS7y
UCT score still <12 points (poorly controlled urticaria)
UCT score deteriorated to <12 points (poorly controlled urticaria)
UCT score improved to > _12 points (wellcontrolled urticaria)
UCT score remained > _12 points (well-controlled urticaria) No response 100% (n 5 6)
*Changes from baseline to 4 weeks after the first omalizumab injection (dose of 300 mg).
Response based on the UAS7 was defined as follows ''no response'' (< _30% improvement of the UAS7 at any time during the 4 weeks after the first omalizumab injection), ''partial response'' (>30% improvement of the UAS7 at any time during the 4 weeks after the first omalizumab injection without achievement of a UAS7 < _6), ''complete response'' (UAS7 < _6 at any time during the 4 weeks after the first omalizumab injection).
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Association study of childhood food allergy with genome-wide association studies-discovered loci of atopic dermatitis and eosinophilic esophagitis
To the Editor:
Food allergy (FA) is a public problem throughout the world and the prevalence rates of IgE-mediated FA in children are increasing in westernized countries.
1 There appear to be both environmental and genetic predisposing factors for FA development; however, the genetic components of FA in children remain largely unexplored.
1 Genome-wide association studies (GWAS) have convincingly identified candidate genes for a wide variety of allergic diseases, and shared susceptibility loci have been found across the diseases. Atopic dermatitis (AD) is a chronic inflammatory skin disease that increases the risk of FA and other immune-mediated inflammatory diseases.
2 Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory disease that is driven by food antigens. 3 Because knowledge on overlapping genetic risk often provides insights into shared biological mechanisms, we examined whether common genetic variants were associated with those related disorders. We conducted an association study of childhood FA using the candidate gene approach, and focused on 19 and 7 susceptibility variants previously reported in GWAS for AD and EoE, respectively (summarized in Table E1 in this article's Online Repository at www.jacionline.org). Furthermore, the strongest known genetic risk factor for AD is FLG null mutations. 2 We additionally assessed the associations of 6 null FLG variants. We recruited patients with FA and conducted an association study. Their clinical information is presented in Table E2 in this article's Online Repository at www.jacionline.org. Detailed descriptions of the genotyping, study population, and statistical analysis can be found in the Methods section in this article's Online Repository at www.jacionline.org.
The combined analysis revealed significant associations between FA and 14 loci, C11orf30/LRRC32, TMEM232/ SLC25A46, TNFRSF6B/ZGPAT, OVOL1, KIF3A/IL13, GLB1, CCDC80, ZNF365, OR10A3/NLRP10, IL2/IL21, CLEC16A/ DEXI, ZNF652, TSLP/WDR36, and STAT6, at the nominal level (P < .05) (see Table I ; also see Table E3 in this article's Online Repository at www.jacionline.org). The possible biases of the analysis are discussed in the Methods section (see Table E4 in this article's Online Repository at www.jacionline.org). Interestingly, the effects of 13 of the 14 loci were in the same direction (Table I) , and more susceptibility loci of AD were associated with FA than were those of EoE. Important roles of esophageal-specific genetic risk variants have been suggested in EoE. 3 Childhood FA seems to have a more similar genetic basis to AD than to EoE, and that implies shared disease mechanisms in FA and AD. Intriguingly, the C11orf30/LRRC32 variant rs11236809 from AD showed an association with childhood FA but the rs55646091 variant from EoE did not. It has been reported that the most associated variant frequently differs at shared loci among major immune-mediated diseases. 4 Thus, further studies are necessary to identify the causal genes and variants at those related loci.
Among those 14 loci, C11orf30/LRRC32, TMEM232/ SLC25A46, KIF3A/IL13, IL2/IL21, TSLP/WDR36, and STAT6 were common loci of allergic diseases and allergy-related phenotypes (see Table E5 in this article's Online Repository at www.jacionline.org). 5 The understanding of disease endotypes, which are defined by specific underlying molecular mechanisms, is considered to help clinicians improve disease management. A recent study has reported that atopy in children is unlikely to represent a true endotype. 6 This study has shown that sensitization to allergens is significantly associated with AD in early childhood. 6 Interestingly, 5 of the 6 loci were associated with allergic sensitization (Table E5 ). Those genetic factors might be involved in an endotype of allergy in early childhood.
In this study, we assessed the associations of a total of 6 FLG null variants, c.3321delA, p.Q1701*, p.S2554*, p.S2889*, p.S3296*, and p.K4022*, which have been reported in Japanese populations. 7 We found a significant association between the 6 FLG null variants and childhood FA (P combined 5 .000055; odds ratio, 1.63; 95% CI, 1.28-2.07) (see Table E6 in this article's Online Repository at www.jacionline.org). Interestingly, p.S2889 was associated with childhood FA in both the primary and validation populations (Table E6 ). Ethnic differences
METHODS

Patient population
In this study, we recruited 65 consecutive adult patients with difficult-totreat CSU (ie, patients with insufficient responses to regular and increased doses of second-generation H 1 -antihistamines), who presented to the urticaria specialty clinic of the Department of Dermatology and Allergy, Charit e-Universit€ atsmedizin Berlin between March 2014 and July 2015 for the initiation of omalizumab therapy (Table E1) . Our study population included CSU patients who also suffered from chronic inducible urticaria (CIndU), but patients were excluded if CIndU was predominant. The study was approved by the responsible ethics committee of the Charit e-Universit€ atsmedizin Berlin (EA1/178/16).
Outcome tools
UCT. The UCT assesses the level of disease control in chronic urticaria patients during the last 4 weeks. E1 It consists of 4 questions with 5 answer options each that are scored from 0 to 4. The UCT score is the sum of all 4 questions with a lowest and highest possible value of 0 (no control) and 16 (complete control), respectively. A score > _12 indicates well-controlled urticaria, while a score of < _11 points toward poor disease control.
E1 None of the included UCT scores had missing items.
UAS. The UAS is the current gold standard to measure disease activity in CSU patients. E2-E4 It is a simple scoring system based on the prospective, once-daily assessment of itch intensity and numbers of wheals on 4-point scales scored from 0 to 3 over a period of 7 days (UAS7). E2 Accordingly, the minimum and maximum UAS7 scores are 0 and 42, respectively. The UAS7 was calculated for the last 7 days of the baseline and the follow-up period. In case < _2 days of UAS7 documentation were missing, the missing daily scores were replaced by the mean daily scores of the remaining, available days of that week (in total, 13 daily scores were replaced in 10 patients in the baseline phase and 5 daily scores in 3 patients during the follow-up phase). When >2 days were missing, the data were excluded from the analyses (data from 9 patients in the baseline phase and from 15 patients in the follow-up phase).
CU-Q 2 oL. The CU-Q 2 oL is the first and currently only disease-specific HR-QoL questionnaire for CSU patients. E5-E7 It contains 23 questions and has a recall period of 2 weeks. All questions have 5 answer options that are scored from 0 to 4. After summing up all available question scores, these are divided by the maximum possible score in that patient (depending on the number of questions answered by that patient) and subsequently multiplied by 100. By applying this method, the total score is transferred to a 0 to 100 scale, which is done to limit the influence of missing items on the total score. Higher CU-Q 2 oL total score values indicate a higher HR-QoL impairment. The CU-Q 2 oL total score was not calculated in case >5 items within the questionnaire were left unanswered, which was the case in 1 patient at baseline and in 3 patients at follow-up. In total, only 109 of 2990 CU-Q 2 oL items were missing (3.6%).
DLQI. DLQI E8 is the most widely used HR-QoL measure for dermatological disorders with a recall period of 1 week. It is a 10-item questionnaire that also has been specifically validated for the use in CSU. E9 The minimum and maximum DLQI scores are 0 and 30 points, respectively. Higher scores are indicative of a stronger HR-QoL impairment. The DLQI score was not computed when >1 item was left unanswered, which was the case in only 1 patient at baseline. In total, only 6 of 1300 DLQI items were missing (0.5%).
PatGA. All patients were asked, at baseline and follow-up, to globally self-rate (1) whether their current CSU treatment during the past 4 weeks was ''sufficient'' or ''not sufficient'' (PatGA-treatment) and (2) how well their urticaria was overall under control during the past 4 weeks on a 5-point Likert scale with the answer options ''not at all,'' ''hardly,'' ''moderately,'' ''well,'' and ''completely'' (PatGA-disease control). PatGA-treatment was missing in 2 and 3 patients at baseline and follow-up, respectively. PatGA-disease control was missing in 4 and 0 patients at baseline and follow-up, respectively. Missing values were not replaced.
Physician's Global Assessment of treatment response. The treating physicians were asked at follow up to globally rate the patients' response to omalizumab on a 3-point scale (PhyGA-treatment response) with the answer options 'no response' (< _30% improvement), 'partial response' (>30% but < _90% improvement), and 'complete' response (>90% improvement). PhyGA-treatment response was missing in one patient and was not replaced.
Data analysis
Responsiveness. To assess the UCT's responsiveness, we computed the mean values of the UCT score, the UAS7, the CU-Q 2 oL total score, and the DLQI score at baseline and follow-up as well as the mean changes of these values. The mean scores were expected to markedly improve in all scores, in other words, to increase in case of the UCT and to decrease in case of the other instruments' scores, because omalizumab has been demonstrated to be an efficacious treatment in CSU in several randomized controlled trials.
E10-E16 Subsequently, we computed the correlations between the UCT score changes and the respective changes in the other scores (Pearson correlation). Our interpretation of the correlation coefficients was as follows: r ; 0.3 weak correlation, r ; 0.5 good correlation, r ; 0.7 strong correlation. The UCT score changes were hypothesized to show at least good correlation with the changes of the UAS7, the CU-Q 2 oL total score, and the DLQI score. In addition, the UCT score changes were expected to show a higher correlation with the score changes of the 2 disease-specific measures UAS7 and CU-Q 2 oL as compared to the less specific DLQI.
In addition, we related the UCT scores and their changes to (1) the PatGAtreatment, (2) the PhyGA-treatment response, as well as (3) the treatment response based on the UAS7 development from baseline to follow-up. To this end, we first dichotomized the UCT results of the patients, based on the established cutoff value of 12 points E1 into patients with ''poorly controlled'' disease and patients with ''well-controlled'' urticaria. Subsequently, we computed the proportions of patients with ''poorly controlled'' urticaria and ''well-controlled'' urticaria who (1) rated their treatment as ''sufficient'' or ''not sufficient'' (PatGA-treatment), who (2) were evaluated by the treating physicians (PhyGA-treatment response) as ''nonresponders,'' ''partial responders,'' or ''complete responders,'' and who (3) were ''nonresponders'' (< _30% improvement of the UAS7), ''partial responders'' (>30% improvement of the UAS7 without achievement of UAS7 < _6), and ''complete responders'' (UAS7 < _6) based on UAS7 changes from baseline to follow-up.
Responsiveness and MID. Responsiveness is defined as the ability of an instrument to detect changes over time in the construct to be measured. E17 It is commonly reported through the MID, also known as minimal important change. A change equal to or higher than the MID can be considered clinically relevant.
To determine the MID of the UCT, we applied 2 anchor-based approaches, (1) the mean change method E18,E19 and (2) ROC curve analysis. E20 For both analyses, the PatGA-disease control was used as external anchor. The mean change method was applied by computing the mean changes of UCT scores from baseline to follow-up in patients exhibiting different PatGA-disease control ratings at these assessments. The MID in this approach is defined as the mean UCT score improvement in patients with a minimal but still perceivable change, that is, patients with a 1-step improvement in their PatGA-disease control rating from baseline to follow-up.
For the ROC curve analysis, patients were dichotomized into subjects with ''improved'' disease control (defined as > _1step improvement in their PatGAdisease control rating from baseline to follow-up) and ''not improved'' disease control (defined as an unchanged or worsened PatGA-disease control rating). Subsequently, the sensitivity and specificity of each possible cutoff point for UCT score changes indicating ''improved disease control'' was computed. In addition, the sum of the percentage of misclassified patients was recorded. Before the ROC curve analysis was performed, we had defined that the correlation between the anchor (PatGA-disease control changes) and the UCT score changes should be at least good (r ; 0.5) in order to ensure the suitability of the anchor.
As an alternative, indirect method to determine the MID, we applied a distributional-criterion approach. In this approach, the baseline UCT's SD is divided by 2, based on reports that one-half of the SD of a PRO measure's mean baseline score is a good approximation of the MID.
E21
Smallest detectable change. The smallest detectable change (SDC) is the smallest change that can be considered a ''real'' change with a 95% confidence.
E19 It is the smallest change of a PRO tool's score beyond the measurement error. The SDC is defined as 1.96 times the SD of the PROs' score changes E22 between 2 independent assessments in stable, unchanged patients. Subjects with an identical PatGA-disease control rating at baseline and followup were included for this analysis.
Because the proportion of stable patients was rather small in the population studied, we decided to additionally determine the SDC in the population from the original UCT publication E1 independently to ensure that the SDC results are accurate. Thirty-three patients were included because they exhibited an unchanged disease severity at 2 independent UCT assessments 4 weeks apart. These patients (22 females, 11 males) had a mean age of 47.4 6 16.5 years and a mean disease duration of 111.3 6 149.4 months. In this population, neither a defined intervention nor resistance to H 1 -antihistamines was a prerequisite for inclusion.
Statistical analysis
Statistical analyses were done using SPSS (IBM SPSS Statistics version 22; IBM Corporation, Armonk, New York, NY). P < _ .05 was considered as statistically significant.
RESULTS
Additional data on the patient population
All included patients had antihistamine-refractory CSU. The majority (77%) was female, and most subjects (82%) exhibited both recurrent wheals and angioedema (Table E1) .
Additional results on the ability of the UCT to detect changes in response to treatment Four weeks after the initiation of omalizumab 300 mg treatment (follow-up), the UCT scores increased by 5.8 6 4.3 points, the UAS7 dropped by 12.4 6 12.4 points, and the CUQ2oL total scores and DLQI scores decreased by 19.2 6 15.1 and 7.5 6 7.5 points, respectively, as compared to baseline (for mean individual changes, see Table E2 ).
The UCT results strongly correlated with changes in the patients' self-evaluation of their treatment efficacy (for PatGAtreatment, see Table E3 ): before initiation of omalizumab 61 of 65 patients (94%) had a UCT score <12 points indicating ''poorly controlled'' disease, while only 4 patients (6%) exhibited a UCT score > _12 points, suggesting ''well-controlled'' disease ( Fig E1) . The majority of patients (90%) with ''poorly controlled disease'' at baseline (UCT score <12 points) also reported that their treatment was not sufficient. Four weeks after the first administration of omalizumab, the majority of patients (62%) exhibited a UCT score indicative of ''wellcontrolled'' urticaria (UCT score > _12 points) and 93% of them indicated that their treatment was sufficient (Fig E1,  Table E3 ).
In addition, the UCT results also correlated with the physicians global assessment of the patients treatment response: 4 weeks after the first omalizumab administration, the treating physicians rated 34 of 64 patients (53%) as ''complete responders,'' 19 patients (30%) as ''partial responders,'' and 11 patients (17%) as ''nonresponders'' (PhyGA-treatment response). While 88% of the ''complete responders'' changed from a UCT score of <12 points at baseline to > _12 points during omalizumab treatment, this was only the case in 17% of the ''partial responders'' and 18% of the ''nonresponders'' (Table E4) .
Additional results on the SDC of the UCT score In this study, 10 patients exhibited a stable, unchanged PatGAdisease control rating at baseline and follow-up. These patients had a mean change of their UCT score of 1.3 6 1.9 points (median, 1.0). The UCT score changes followed a normal distribution (P 5 .13, . Accordingly, the SDC of the UCT score is 3.7 points (1.96*SD). Only 2 patients (20%) exhibited an improvement of their UCT score by 3 points or more, in other words, 80% are classified correctly as not meaningfully improved when a MID of 3 points is applied.
In the independent patient sample from the original UCT publication, E1 33 subjects exhibited a stable disease status between 2 UCT assessments 4 weeks apart. The mean difference between the first and the second UCT application was 0.5 6 1.9 points (median: 0). Based on this population, the SDC of the UCT score is 3.8 points. Only 5 patients with stable disease (15%) exhibited an improvement of their UCT score by 3 points or more, that is, 85% are classified correctly as not meaningfully improved when a MID of 3 points is applied. Because the UCT score changes did not fulfil the criteria for normal distribution in this patient sample (P 5 .018, Shapiro-Wilk test), we also investigated the performance of the calculated SDC in this population. Notably, only 3 patients (9%) reported a UCT score change of >3.8 points, suggesting the validity of the applied method of SDC calculation also in this sample.
DISCUSSION
Levels of MID and SDC
As explained in the original article of this repository, we regard a MID of 3 points as most appropriate for UCT score changes. With this MID, at least 80% of patients with ''truly not improved'' disease control are correctly classified as not improved by the UCT. Moreover, a definition of the UCT's MID to be 4 instead of 3 points, at least in our population, would go along with an unchanged specificity but a lower sensitivity of identifying subjects with ''truly improved'' urticaria control. The proportion of misclassified patients would increase.
The SDC of the UCT was found to be 4 points in this study, in other words, the smallest change of the UCT score beyond the measurement error. While the number of 10 patients for the SDC calculation was small, and its result might therefore be questioned, we were able to reproduce the same SDC value in a second, independent, and larger patient population from the original UCT validation study.
E1 It may appear confusing that the SDC with 4 points is slightly larger than the MID with 3 points. However, this is a well-known phenomenon in clinimetrics. For most measurement instruments, the SDC is greater than the MID. E22 A major reason for this is that the criterion for the SDC computation (95% confidence) is very conservative, whereas the criteria for the MID need to be less rigorous.
Study limitations
Limitations of this study include (1) that the patient sample consisted only of H 1 -antihistamine-refractory and only of CSU patients, (2) that the data on the MID was obtained in patients that received only 1 type of treatment adjustment, known to have a large effect size, (3) that all patients were recruited in a specialized, tertiary referral center, and (4) that all included subjects were adults. Accordingly, we cannot fully exclude that the MID might be overestimated in this setting and that slightly different results might be obtained in other populations, such as patients with less-severe urticaria, patients with CIndU but not CSU, or children and adolescents. Further limitations of this study are that the populations to determine the SDC were small and that it may be questioned whether the distributions of the UCT score changes are normal enough for the SDC calculations. Although, the SDC results were found to be similar in the 2 independent populations studied, the SDC of the UCT remains to be confirmed in future studies. 
FIG E2.
Changes of the UCT score correlate with changes of the UAS7 score (A), the CU-Q 2 oL total score (B), and the DLQI score (C). Changes are measured from baseline to 4 weeks after the first omalizumab injection (300 mg). *CIndU comprise: delayed pressure urticaria (n 5 1), symptomatic dermographism (n 5 7), cholinergic urticaria (n 5 5), and cold urticaria (n 5 1). Two patients had 2 different CIndUs in addition to their CSU.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 6 (2) 3 (1) Values are percentages (n). *Patients globally assessed whether their treatment was sufficient during the last 4 weeks or not. Four weeks after the first omalizumab injection (300 mg). àUCT scores of 2, 7, 8, and 9 points. §UCT scores ranged from 4 to 11 points. kUCT scores of 12 and 13 points.
{UCT scores of 12 points in both patients. 
Values are percentages (n). *Changes from baseline to 4 weeks after the first omalizumab injection (300 mg). Physicians globally assessed the treatment response as ''no response'' (< _30% improvement of the disease), ''partial response'' (>30% but < _90% improvement of the disease), ''complete response'' (>90% improvement of the disease).
